[
    "{\"step_by_step_thinking\": \"Document 1 and 2 suggest that Algenpantucel-L immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer may improve survival. However, Document 4 shows that Algenpantucel-L immunotherapy did not improve survival in patients with borderline resectable or locally advanced unresectable PDAC receiving SOC neoadjuvant chemotherapy and chemoradiation. Therefore, the effectiveness of Algenpantucel-L for pancreatic cancer seems to be dependent on the stage of the disease and the specific treatment regimen.\", \"answer_choice\": \"A\"}"
]